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For more information on confirming a diagnosis of schizoaffective disorder, see the J Clin Psychlopedia activity "Differentially Diagnosing Schizoaffective Disorder."
Evaluate the Predictors of Outcome
After confirming a diagnosis of schizoaffective disorder, clinicians should evaluate the patient's predictors of outcome, which include previous levels of functioning, number of prior episodes, nature of psychotic symptoms, and extent of cognitive impairment. Initially assessing these features is critical in determining an effective, individualized treatment plan and anticipating the patient's course of illness and outcome.
Previous functioning. Patients with schizoaffective disorder tend to
have levels of social and occupational functioning that are better than those with schizophrenia but worse than those with bipolar disorder. 2 Using a cluster analysis, Lipkovich et al 3 determined that the better the social and occupational functioning that patients with schizoaffective disorder have at baseline, the more likely they will have good treatment outcomes. Nature of psychosis. By definition, patients with schizoaffective disorder have psychotic symptoms, but the persistence and presentation of those symptoms can predict outcomes for patients. For example, patients with less persistent psychotic symptoms have a better prognosis than those with more persistent psychosis. 4 And, patients with mood-incongruent psychotic symptoms, ie, inappropriate to the mood episode, are likely to have poor outcomes (AV 1), including poor psychosocial functioning as well as the presence of major psychotic symptoms.
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Cognitive impairment. Because cognitive impairment is closely related to functioning, clinicians should evaluate deficits in patients with schizoaffective disorder. The premorbid intellectual, language, and behavioral functioning of patients with schizoaffective disorder was found to be similar to that of schizophrenia patients and worse than that of bipolar disorder patients. 6 Additionally, one study 7 found that neurocognitive performance was a better predictor of occupational functioning, ie, employment status and the ability to obtain a job, than were the clinical symptoms of schizoaffective disorder.
Implement Pharmacotherapy
After evaluating each patient's predictors of outcome, formulate an individualized treatment plan based on the available evidence, which is categorized below by medication in order of the studies' methodological strength. The amount of data for schizoaffective disorder is limited because most trials have examined subsamples of schizoaffective disorder in addition to schizophrenia. Very limited data is available for compounds not listed below, including conventional antipsychotics, lithium, or valproate. Paliperidone. This is the only compound that has been assessed in a specifically designed, large, randomized, placebo-controlled study and found that the atypical antipsychotic paliperidone ER (12 mg/d) significantly improved total scores on the PANSS (AV 2, P = .003), the CGI-S-SCA (P < .001), the YMRS (for those with prominent manic symptoms, P < .001), and the HDRS (for those with prominent depressive symptoms, P < .05) compared with placebo. Overall, the medication was well tolerated; headache and tremor were the most common adverse events, although headache was reported more often in the placebo group.
Ziprasidone and aripiprazole. Pooled data from 2 double-blind placebocontrolled trials 9 of schizophrenia, focusing on the subset of patients with schizoaffective disorder (n = 115) reported significant dose-related improvements with ziprasidone (with 160 mg/d having the largest effect) on the BPRS total score, BPRS Core Items subscale, BPRS Manic Items, and the CGI-S (P < .01 for all) compared with placebo. The most common medicationinduced adverse events were general pain and headache, but a notable lack of many adverse events, such as EPS and sexual dysfunction, was apparent. Risperidone. In a double-blind comparative study 13 of risperidone (mean dose = 5.5 mg/d) and haloperidol (mean dose = 10.8 mg/d), patients with schizoaffective disorder (N = 62) had symptomatic improvement with both medications on the PANSS, the CARS-M, and the HDRS, but the differences were not significant. Risperidone was better tolerated than haloperidol, with significantly more haloperidol-treated patients experiencing EPS (P = .03). In an open study 14 of schizoaffective disorder or bipolar disorder (N = 541), the addition of risperidone (mean dose = 3.9 mg/d) to mood stabilizers showed significant improvement on the YMRS, the HDRS, the PANSS, and the CGI (P < .0001 for all). The adjunctive risperidone was well tolerated, with only 2.4% of subjects experiencing weight gain, which was the most commonly reported adverse event.
Treatment adherence. To ensure that patients have the opportunity to achieve remission, clinicians should educate patients about their illness to help them have awareness and insight, address any concerns patients have about taking medication, and identify potential safety problems and barriers to adherence, such as co-occurring personality or substance use disorders. 
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Add Psychoeducation
When patients have reached remission, which is the time when they are best suited to understand, learn, and develop strategies to cope with the illness, psychoeducation can help to improve patient outcomes by increasing illness insight and awareness, improving treatment adherence, and helping patients and caregivers identify early signs of relapse. Although no studies specific to schizoaffective disorder are available, data from bipolar disorder and schizophrenia trials may be helpful. In studies of schizophrenia, psychoeducation improved patients' knowledge of their illness, 15, 16 treatment adherence, 17 and quality of life 15 as well as reduced rehospitalization rates for those with 2 to 5 previous psychotic episodes (AV 4). 17 In a study 18 of bipolar disorder, group psychoeducation reduced the number of relapses and recurrences, reduced the number and length of hospitalizations, and increased the time to any mood recurrence.
Additionally, caregiver psychoeducation has been shown to reduce the recurrence and increase the time to intervention for any mood episode.
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Individualize Treatment
Individualizing treatment for patients with schizoaffective disorder requires merging the evidence base from schizoaffective disorder, schizophrenia, and bipolar disorder and tailoring treatment plans to each patient's specific schizoaffective subtype, eg, bipolar type or depressive type.
Bipolar type. Atypical antipsychotics should be given for patients with schizoaffective disorder, bipolar type, particularly when psychotic and manic symptoms are present. Evidence in bipolar disorder suggests that combining an atypical antipsychotic and mood stabilizer is the preferred first-line treatment 20 ; both specific medication choices should be guided by individual symptom profiles and treatment tolerability. After the patient reaches remission, psychoeducation should be instituted and the medication regimen that helped the patient achieve remission should be continued through the maintenance phase; atypical antipsychotic monotherapy is also acceptable during this phase of treatment.
Depressive type. Evidence for the depressive subtype of schizoaffective disorder is so limited that the recommendations here are from clinical practice rather than clinical trials. Generally, using an atypical antipsychotic plus an antidepressant or a mood stabilizer should be sufficient to manage schizoaffective disorder, depressive type, but again, the individual patient's symptomatic profile and tolerability should guide specific medication choices.
Additionally, psychoeducation should be implemented once the patient achieves remission and enters the maintenance phase of treatment. 
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